005500 — Samjin Pharmaceutical Co Income Statement
0.000.00%
- KR₩255bn
- KR₩360bn
- KR₩292bn
- 77
- 56
- 50
- 69
Annual income statement for Samjin Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS/A | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 241,926 | 235,165 | 250,070 | 274,032 | 292,129 |
Cost of Revenue | |||||
Gross Profit | 120,714 | 110,516 | 117,832 | 117,734 | 116,681 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 196,927 | 202,832 | 216,120 | 250,065 | 271,628 |
Operating Profit | 44,999 | 32,333 | 33,951 | 23,967 | 20,501 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 21,872 | 32,830 | 34,911 | 25,226 | 15,557 |
Provision for Income Taxes | |||||
Net Income After Taxes | 11,881 | 27,879 | 28,404 | 21,901 | 18,906 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 11,881 | 27,879 | 28,404 | 21,894 | 18,908 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 11,881 | 27,879 | 28,404 | 21,894 | 18,908 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 960 | 2,239 | 2,238 | 1,640 | 1,450 |
Dividends per Share |